|
Match
|
Document |
Document Title |
|
|
US20090292020 |
USE OF CALCIUM SALT OF POLYENOIC ACID IN MEDICAL AND COSMETIC FIELD
The present invention relates to a process for applying calcium polyenoic acid to medical cosmetology, wherein calcium polyenoic acid, calcium octadecadienic acid and calcium calendic acid are made...
|
|
|
US20090291066 |
COMPOSITION AND METHOD OF TREATING FACIAL SKIN DEFECT
This invention relates to a subcutaneous deliverable composition containing an agonist of the peroxisome proliferator-activated receptor-gamma, and a method for treating facial skin defects in a...
|
|
|
US20090286879 |
Preventive or Therapeutic Drug for Alzheimer-Type Dementia
It is intended to provide a highly safe preventive or therapeutic drug for Alzheimer-type dementia which can replace the conventional therapies currently used for Alzheimer-type dementia or which...
|
|
|
US20090285850 |
Oral Carotenoid Supplementation Methods for Improving the Health and Appearance of Skin
Provided herein are oral skin care supplements and nutraceutical compositions and methods of use for improving the health and appearance of skin. Also provided are nutraceutical compositions that,...
|
|
|
US20090281185 |
CRYSTALLINE LEUKOTRIENE B4
Leukotriene B 4 , 5S,12R-dihydroxy-6,8,10,14(Z,E,E,Z)-eicosatetraenoic acid, is a twenty carbon tetra-unsaturated fatty acid. No crystal forms of leukotriene B 4 (LTB 4 ) are known in the art. The...
|
|
|
US20090275658 |
Method for Producing a Raw Oil from Mixtures of Micro-Organisms and Plants, Oil Produced According to Said Method and Specific Uses of the Thus Produced Oil and, Optionally, Additional Refined Oil
The invention relates to a method for producing a raw oil from micro-organisms and plants, oil produced according to said method and specific uses of the thus produced oil and, optionally,...
|
|
|
US20090270504 |
Treatment of Huntington's Disease With EPA
Analysis of the huntington gene provides a method for identifying patients likely to respond to treatment of Huntington's disease with eicosapentaenoic acid, EPA.
|
|
|
US20090270503 |
NUTRITIONAL SUPPLEMENTS
The present disclosure relates to novel nutritional methods and compositions containing essential fatty acids which optimize embryonic, fetal and child neurological development and provides...
|
|
|
US20090270498 |
Lipoxin Compounds and Their use in Treating Cell Proliferative Disorders
Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which...
|
|
|
US20090264529 |
ACTIVATORS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
Activators of peroxisome proliferator-activated receptors comprising a polyprenyl compound, preferably (2E,4E,6E,10E)-3,7,11,15-tetramethyl-2,4,6,10,14-hexadecapen
taenoic acid, as an active...
|
|
|
US20090264528 |
SERINE PALMITOYLCOA TRANSFERASE (SPT) INHIBITION BY MYRIOCIN OR GENETIC DEFICIENCY DECREASES CHOLESTEROL ABSORPTION
A first aspect of the invention provides a method of screening cholesterol absorption inhibitors, including: administering to a mammal a biologically effective amount of a candidate SPT inhibitor;...
|
|
|
US20090264520 |
LIPID-CONTAINING COMPOSITIONS AND METHODS OF USE THEREOF
Lipid compositions comprising nuts, seeds, oils, legumes, fruits, grains, and dairy useful in specified amounts as dietary supplements and diet plans designed around and including the...
|
|
|
US20090258945 |
Lipoxin Compounds and Their Use in Treating Cell Proliferative Disorders
Compounds having the active site of natural lipoxins, but a longer tissue half-life are disclosed. In particular, 15-epi-lipoxins and their use in ameliorating undesired cell proliferation, which...
|
|
|
US20090258084 |
Mono and Combination Therapy with a M1/M4 Muscarinic Agonist (Sabcomeline) for Treatment of Cognitive Disorders in Schizophrenia
The invention relates to the use of a functional muscarinic M1/M4 receptor agonist such as the functional muscarinic M1/M4 receptor agonist or a pharmaceutically acceptable salt thereof, in...
|
|
|
US20090258081 |
NEW PLANT DERIVED SEED EXTRACT RICH IN ESSENTIALLY FATTY ACIDS DERIVED FROM SALVIA HISPANICA L. SEED: COMPOSITION OF MATTER, MANUFACTURING PROCESS AND USE
A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAs in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-100% of C-18 mono-unsaturated fatty acid, 1-5% of...
|
|
|
US20090253791 |
Compositions and Methods For Preventing Or Treating Inflammatory Bowel Disease
Compositions comprising docosahexaenoic acid (DHA) and optionally one or more fatty acids selected from the group consisting of eicosapentaenoic acid (EPA), arachidonic acid (ARA), linoleic acid...
|
|
|
US20090247634 |
Methods for identifying modulators of eoxin formation
A method for identifying a compound for modulating the formation of 14,15-LTC 4 (Eoxin C 4 ; EoxC 4 ), 14,15-LTD 4 (Eoxin D 4 ; EoxD 4 ), or 14,15-LTE 4 (Eoxin E 4 ; EoxE 4 ) in a biological...
|
|
|
US20090247633 |
NUTRIENT EXTRACTS DERIVED FROM GREEN PLANT MATERIALS
An extract from green plant materials includes controlled concentrations of nutritional components. In one embodiment, the nutritional components include at least one xanthophyll, at least one...
|
|
|
US20090239945 |
Oral Composition with an Antiageing Effect on the Skin
A composition which is adapted for oral consumption and which comprises: (i) a PPAR ligand; such as EPA or DHA (ii) an oestrogen receptor binding agent; such as soy isoflavones (iii) an agent that...
|
|
|
US20090239927 |
Statin and Omega-3 Fatty Acids For Lipid Therapy
A method of lipid therapy, comprising providing a subject group having a baseline triglyceride level of 200 to 499 mg/dl and being at or near its low-density lipoprotein cholesterol (LDL-C) level...
|
|
|
US20090238866 |
CHEWABLE CAPSULES
The invention provides an orally administrable chewable capsule comprising a capsule shell enclosing an oil-in-water emulsion in which the aqueous phase is gelled, or an oil droplet-containing...
|
|
|
US20090234008 |
Method of using catalpic acid to treat and prevent dyslipidemia, type 2 diabetes, and associated disorders
A method of treating and preventing dyslipidemia, cardiovascular disease, type 2 diabetes, obesity and other diseases associated with the Metabolic Syndrome and of increasing the expression of...
|
|
|
US20090234007 |
Unsaturated Fatty Acids as Thrombin Inhibitors
A preparation having at least one unsaturated fatty acid and the use of at least one unsaturated fatty acid having a chain length of 18 or 20 carbon atoms and of plant drugs containing the...
|
|
|
US20090234006 |
Method for Producing Arachidonic Acid and/or Eicosapentaenoic Acid in Useful Transgenic Plants
The invention relates to a method for producing arachidonic acid and/or eicosapentaenoic acid in useful transgenic plants, according to which nucleic acids, which encode polypeptides with...
|
|
|
US20090227678 |
Process for obtaining lipid form cells
The present invention relates to a process for obtaining lipid from a composition comprising cells and water, said process comprising contacting the composition with a desiccant, and recovering the...
|
|
|
US20090226481 |
Compositions Ameliorating a Reduced Diurnal Activity and/or Depressive Symptoms
A composition having an activity of ameliorating the reduced amount of diurnal activity and/or depressive symptoms, comprising arachidonic acid and/or a compound having arachidonic acid as a...
|
|
|
US20090222955 |
DELTA 6 DESATURASES FROM PRIMULACEAE, EXPRESSING PLANTS AND PUFA-CONTAINING OILS
The present invention relates to an improved method for the specific production of unsaturated ω-3 fatty acids and a method for the production of triglycerides having an increased content of...
|
|
|
US20090221705 |
OMEGA 3
A process for the preparation of a water soluble unsaturated fatty acid salt from a crude composition comprising at least one non-water soluble or sparingly water soluble unsaturated fatty acid or...
|
|
|
US20090215897 |
Method for treatment and prevention of respiratory insufficiency
The invention relates to the use of a composition comprising eicosapentaenoic acid 5 (EPA, n-3), docosahexaenoic acid (DHA, n-3) and stearidonic acid (STA) and having a weight ratio STA/DHA of at...
|
|
|
US20090215896 |
REELIN DEFICIENCY OR DYSFUNCTION AND METHODS RELATED THERETO
A method of measuring Reelin as a biomarker, to non-destructively assess or predict DHA levels in the brain and in other, currently inaccessible or difficult-to-access, key components of the...
|
|
|
US20090215895 |
Therapeutic and carrier molecules
The present invention relates generally to compounds comprising a hydrocarbon chain portion and more particular to compounds comprising chemical derivatizations of the hydrocarbon chain which are...
|
|
|
US20090209644 |
LIPOTOXICITY RELIEVING AGENT
In view of the situation that a clinically acceptable medical agent which has the action of preventing and relieving the lipotoxicity with no significant side effects is not yet provided, such...
|
|
|
US20090209601 |
USE OF RXR AGONISTS FOR THE TREATMENT OF OSTEOARTHRITIS
Disclosed herein are methods of preventing and treating osteoarthritis through the use of RXR agonists.
|
|
|
US20090208468 |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
The present disclosure relates to oligodeoxynucleotides that suppress an immune response. Methods are disclosed for preventing or treating an immune-mediated disorder, such as, but not limited to,...
|
|
|
US20090203788 |
METHOD OF ENHANCING REPRODUCTIVE FUNCTION OF MAMMALS BY FEEDING OF CONJUGATED LINOLEIC ACIDS
This invention provides methods for improving reproductive performance of lactating dairy cows and other mammals. The method in the case of cows comprises feeding to the cows, a composition...
|
|
|
US20090203787 |
VERY LONG CHAIN POLYUNSATURATED FATTY ACIDS, METHODS OF PRODUCTION, AND USES
The present invention relates to processes for production of Very Long Chain Polyunsaturated Fatty Acids (VLC-PUFAs). The present invention also relates to compositions (e.g., nutritional...
|
|
|
US20090203786 |
Methods and Composition for Improving Cognitive Function
Compositions and methods for enhancing cognitive function in animals are disclosed. The compositions and methods utilize long chain polyunsaturated fatty acids.
|
|
|
US20090203780 |
Use of a Polyunsaturated Fatty Acid Compound
A polyunsaturated fatty acid having 20 carbon atoms and four double bonds, or a derivative thereof, in an orally administrable form, can be used to treat or prevent obesity and/or for weight...
|
|
|
US20090203778 |
FATTY ACID ANALOGUES, I.E. INCLUDING DHA DERIVATIVES FOR USES AS A MEDICAMENT
A compound of formula (I) wherein R 1 and R 2 are different and each is chosen from a methyl group and a hydrogen atom; wherein X is chosen from a carboxylic acid group, a carboxylate group, a...
|
|
|
US20090203655 |
PROPHYLACTIC DOCOSAHEXAENOIC ACID THERAPY FOR PATIENTS WITH SUBCLINICAL INFLAMMATION
This invention is directed to methods and compositions which impede the development and progression of diseases associated with subclinical inflammation. Subclinical inflammation is commonly...
|
|
|
US20090202668 |
Use of a polyphenol in the treatment of the metabolic syndrome and endothelial dysfunction or other vascular sequellae
The invention relates to the use of a polyphenol in the manufacture of a nutriceutical, a food, a food supplement or a medicament for the prophylactic or therapeutic treatment of endothelial...
|
|
|
US20090202519 |
Compositions and methods for treating gram positive bacterial infection in a mammalian subject
Compositions and methods are provided for treating Gram positive bacterial infection in a mammalian subject. Compositions and methods are further provided for treating Gram positive bacterial skin...
|
|
|
US20090197955 |
METHODS OF IMPROVING DHA DEPOSITION AND RELATED FUNCTION AND/OR DEVELOPMENT
The present invention provides for improved deposition of DHA in human or animal tissues by incorporating healthy lipids containing stearidonic acid into humans or animal through prolonged food or...
|
|
|
US20090192226 |
Materials and Methods for Treatment of Pathological Ocular Vascular Proliferation
The subject invention provides for the administration of docosahexaenoic acid in preventing pathological proliferation of blood vessels. The compositions of the subject invention are particularly...
|
|
|
US20090192201 |
Composition and method for treating and preventing musculoskeletal and connective tissue disorders
The present invention relates to a pharmaceutical composition and method for treating and preventing musculoskeletal and connective tissue diseases of unknown etiology, such as different forms of...
|
|
|
US20090192040 |
PLANT SUPPORT FORMULATION, VEHICLE FOR THE DELIVERY AND TRANSLOCATION OF PHYTOLOGICALLY BENEFICAL SUBSTANCES AND COMPOSITIONS CONTAINING SAME
The invention provides a plant supporting formulation which is also suitable for use as a delivery vehicle, or a component of a delivery vehicle, for the delivery of one or more phytologically...
|
|
|
US20090182050 |
Salts of Fatty Acids and Methods of Making and Using thereof
Disclosed are methods of making salts of fatty acids (e.g., marine oils) and to salts prepared by the disclosed methods. Methods of using the disclosed salts are also disclosed.
|
|
|
US20090182049 |
Pharmaceutical Composition and Method for Treating Hypertriglyceridemia and Hypercholesterolemia in Humans
A method for the treatment or prophylaxis of hypertriglyceridemia and hypercholesterolemia without concomitantly increasing LDL-serum cholesterol, in a human subject requiring such treatment, which...
|
|
|
US20090182022 |
Treatment of Fatty Liver
Methods and compositions comprising peroxisomal and/or mitochondrial beta oxidation stimulating agents to reverse or resolve, slow the progression of, treat or prevent the development of fatty...
|
|
|
US20090181109 |
Nanoveson™: treatment, biomarkers and diagnostic tests for liver diseases and comorbid diseases
A method of treatment of liver diseases and comorbid diseases is disclosed wherein an oral dose of lipids in an amount effective to trigger the release of cholecystokinin (CCK) into the duodenum to...
|